Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) receptor , is demonstrating promising data in early clinical assessments . Current inquiry https://bookmarkuse.com/story21179440/retatrutide-emerging-studies-and-possible-medical-uses